@article {ITO3931, author = {TAKAHIKO ITO and YOSHITAKA HONMA and HIDEKAZU HIRANO and HIROKAZU SHOJI and NATSUKO OKITA and SATORU IWASA and ATSUO TAKASHIMA and KEN KATO and NARIKAZU BOKU}, title = {S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma}, volume = {39}, number = {7}, pages = {3931--3936}, year = {2019}, doi = {10.21873/anticanres.13545}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC). In this retrospective study, we evaluated the efficacy and safety of S-1 monotherapy as a salvage line treatment for RM-ESCC, focusing on the reasons for discontinuation of prior FP. Materials and Methods: The subjects of this study had RM-ESCC and received S-1 after failure of FP. Results: Eleven patients were enrolled. Nine patients were refractory and two were intolerant to prior FP. The median progression-free survival and overall survival time were 3.0 and 11.7 months, respectively. Overall response rate was 22.2\% and disease control rate of the 11 patients was 36.4\%. Median relative dose intensity of 5-FU was 100\% (range=85-100\%). Conclusion: S-1 efficacy in RM-ESCC when given after FP was modest. Favorable OS may be attributed to good local control rather than to the efficacy of S-1 monotherapy.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/39/7/3931}, eprint = {https://ar.iiarjournals.org/content/39/7/3931.full.pdf}, journal = {Anticancer Research} }